Press Release:

CYTOCHROMA TO PRESENT AT UPCOMING INVESTOR CONFERENCES

Markham, Ontario, Canada — September 7, 2011 — Cytochroma today announced that the Company will be presenting a corporate overview at the following investor conferences:

• Charles W. Bishop, Cytochroma’s President and Chief Executive Officer will be presenting at the Stifel Nicolaus Healthcare Conference 2011 at 4:25 PM ET on Wednesday, September 7, 2011 at the Four Seasons Hotel in Boston.

• Eric J. Messner, Cytochroma’s Chief Operating Officer will be presenting at the RW Baird 2011 Health Care Conference at 1:45 PM ET on Thursday, September 8, 2011 at The New York Palace Hotel in New York City.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD).  The Company specializes in developing new therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD.  Cytochroma also has a portfolio of CYP24 and phosphate-uptake inhibitors in early stage development.

For information contact:

Investors:
Gordon Ngan
Executive Director, Corporate Development
Tel: +1 (905) 479-5306 ext. 333
gngan@cytochroma.com

Cytochroma Media:
Robert Stanislaro (Financial Dynamics)
Tel: +1 (212) 850-5657
robert.stanislaro@fd.com

< go back >